BPC-157Recommended
Studied for gut healing, tissue and tendon repair, and anti-inflammatory effects.
Policy and patient health
Better rules. Safer patients.
AAPM (American Academy of Peptide Medicine) works on both sides of peptide medicine: the policy decisions that determine whether Americans can obtain peptide therapies, and the clinical and quality standards that keep those therapies safe once they do.
01 · Policy
Advocating for Safe, Legal Access
Advocating to place these peptides in Category 1 so patients can obtain them through licensed U.S. compounding pharmacies, under a valid prescription and physician oversight.
- Advocate for Category 1 classification
- Support licensed compounding access
- Promote physician-supervised use
- Engage with FDA and PCAC
02 · Patient health
Ending the Gray-Market Danger
Replacing unregulated online and international sources with regulated channels held to USP 795 and 797 standards for sterility, potency, and purity.
- USP 795 and 797 standards
- Sterility and potency testing
- Accredited compounding only
- Patient safety frameworks
Flagship Event
Annual Conference — Washington, D.C.
Each September, AAPM (American Academy of Peptide Medicine) convenes clinicians, researchers, and policymakers for scientific programming, peer exchange, and direct policy engagement in the nation's capital.
PepMed 2026 • Washington, DC
Thank you for making PepMed 2026 a success
The first annual congress of the American Academy of Peptide Medicine brought physicians, pharmacists, researchers, and policymakers together in Washington, DC. Details for the next PepMed Congress will be announced soon.
Hearing results • July 23-24, 2026
Where each peptide stands
The FDA Pharmacy Compounding Advisory Committee reviewed seven peptides and voted to recommend six for the 503A bulks list. The FDA now makes the final call through formal rule-making.
TB-500Recommended
A Thymosin Beta-4 fragment studied for muscle repair and recovery.
KPVRecommended
A tripeptide with documented anti-inflammatory and gut-supportive properties.
MOTs-CRecommended
A mitochondrial-derived peptide studied for metabolic regulation.
DSIPNot recommended
Delta sleep-inducing peptide, studied for sleep and stress response.
SemaxRecommended
Studied for cognitive support and neuroprotection.
EpitalonRecommended
Studied for cellular aging and circadian regulation.
A committee recommendation is not FDA approval and does not change access rules on its own. These compounds remain prescription-only and require individualized physician evaluation through a licensed provider and an accredited compounding pharmacy.
See the full resultsState of play
How we got here
The 2023 restrictions did not eliminate demand. They eliminated regulation. This is the path back to physician-supervised, regulated access.
- 2023
14 widely used peptides are placed on the Category 2 restricted list, pushing patients toward unregulated sources.
- Feb 2026
HHS signals intent to begin restoring safe, physician-supervised, legally compounded access.
- Apr 15, 2026
Peptides are formally removed from the do-not-compound list, effective within seven calendar days.
- Jul 23-24, 2026
At its hearing on the FDA White Oak Campus, the PCAC votes to recommend six of seven peptides for the 503A bulks list.
- Next
The FDA weighs the recommendation in formal rule-making. AAPM keeps pressing for a final rule that restores regulated access.
Why the American Academy of Peptide Medicine (AAPM)
The credibility behind the Academy
Bipartisan leadership
Our founding advisory board includes former governors from both parties, signaling that patient access to safe peptide medicine transcends party lines.
Clinical and regulatory expertise
Our board pairs practicing physicians, pharmacists, and nurses with FDA regulatory attorneys, pharmacy law experts, and former state officials.
A unified field
Each September, AAPM (American Academy of Peptide Medicine) convenes physicians, researchers, and policymakers in Washington, D.C. for scientific programming and direct policy engagement.
The Hearing Is Over. The Work Is Not.
Next step • FDA rule-making
The committee's yes votes are a recommendation, not a final rule. Tell your representatives that patients need safe, regulated access to peptide therapy.